Pharmaceuticals, Biotechnology and Life Sciences
SBTI ID
40008085
Localisation
United States of America
Northern America
Secteur d'activité
Pharmaceuticals, Biotechnology and Life Sciences
Type d'organisation
Corporate
Dernière mise à jour
09/01/2025
Statut
Classification
1.5°C
Année cible
2030
Statut
Targets set
Classification
1.5°C
Année cible
2045
Overall Net-Zero Target: Moderna, Inc. commits to reach net-zero greenhouse gas emissions across the value chain by 2045. Near-Term Targets: Moderna, Inc. commits to reduce absolute scope 1 and 2 GHG emissions 90% by 2030 from a 2021 base year. Moderna, Inc. commits that 85% of its suppliers by emissions covering purchased goods and services, capital goods and upstream transportation and distribution, will have science-based targets by 2028. Long-Term Targets: Moderna, Inc. commits to maintain a minimum of 90% absolute scopes 1 and 2 GHG emissions from 2030 through 2045 from a 2021 base year. Moderna, Inc. also commits to reduce absolute scope 3 GHG emissions emissions 90% by 2045 from a 2021 base year.
Statut
Targets setAnnée cible
2045
Statut
BA1.5 memberDate d'engagement
16/06/2022
The targets covering greenhouse gas emissions from company operations (scopes 1 and 2) are consistent with reductions required to keep warming to 1.5°C
ISIN
US60770K1079
LEI
549300EI6OKH5K5Q2G38
Source : Science Based Targets initiative | Données publiques